Receptors, Androgen

"Receptors, Androgen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.

Descriptor ID	D011944
MeSH Number(s)	D12.776.826.750.150
Concept/Terms	Receptors, Androgen Receptors, Androgen Androgen Receptor Receptor, Androgen Androgen Receptors Dihydrotestosterone Receptors Testosterone Receptor Receptors, Androgens Androgens Receptors Receptors, Dihydrotestosterone Receptors, Stanolone Stanolone Receptors Stanolone Receptor Receptor, Stanolone 5 alpha-Dihydrotestosterone Receptor 5 alpha Dihydrotestosterone Receptor Receptor, 5 alpha-Dihydrotestosterone alpha-Dihydrotestosterone Receptor, 5 Receptor, Testosterone

Below are MeSH descriptors whose meaning is more general than "Receptors, Androgen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Receptors, Cytoplasmic and Nuclear [D12.776.826]
Receptors, Steroid [D12.776.826.750]
Receptors, Androgen [D12.776.826.750.150]

Below are MeSH descriptors whose meaning is related to "Receptors, Androgen".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Androgen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Androgen" by people in this website by year, and whether "Receptors, Androgen" was a major or minor topic of these publications.

Bar chart showing 110 publications over 31 distinct years, with a maximum of 8 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	0	1	1
1997	1	1	2
1998	4	3	7
1999	1	0	1
2000	2	1	3
2001	2	1	3
2002	4	3	7
2003	4	3	7
2004	3	3	6
2005	1	0	1
2006	3	1	4
2007	1	1	2
2008	3	0	3
2009	5	0	5
2010	6	2	8
2011	6	1	7
2012	3	3	6
2013	0	1	1
2014	1	2	3
2015	3	1	4
2016	1	0	1
2017	2	0	2
2018	2	2	4
2019	0	1	1
2020	0	1	1
2021	3	1	4
2022	0	5	5
2023	0	3	3
2024	5	1	6
2025	1	0	1

Below are the most recent publications written about "Receptors, Androgen" by people in Profiles.

Chahdi A, Jorgez C, Rosenfeld JA, Neetu N, Seth A. Androgen receptor ubiquitination links KCTD13 to genitourinary tract defects. FASEB J. 2025 Feb 28; 39(4):e70406.

View in: PubMed
Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, Welti J, Sharp A, Ryan NK, Knudsen LA, Schiewer MJ, DeArment EG, Janas T, Su XA, Butler LM, de Bono JS, Frese K, Brooks N, Pegg N, Knudsen KE, Shafi AA. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. Oncogene. 2024 Oct; 43(43):3197-3213.

View in: PubMed
Karliner J, Liu Y, Merry DE. Mutant androgen receptor induces neurite loss and senescence independently of ARE binding in a neuronal model of SBMA. Proc Natl Acad Sci U S A. 2024 Jul 16; 121(29):e2321408121.

View in: PubMed
Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, Chen HZ, Hamann MT. Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice. Mol Oncol. 2024 Aug; 18(8):1966-1979.

View in: PubMed
McKay RR, Morgans AK, Shore ND, Dunshee C, Devgan G, Agarwal N. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. Cancer Treat Rev. 2024 May; 126:102726.

View in: PubMed
Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, O'Connor C, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowski KA, Wang L, Dehm SM, Nevalainen MT. Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling. Sci Adv. 2024 Mar; 10(9):eadi2742.

View in: PubMed
Chahdi A, Jorgez C, Seth A. Regulation of androgen receptor stability by the ?1 Pix/STUB1 complex. FASEB J. 2024 Feb; 38(2):e23408.

View in: PubMed
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023 07 22; 402(10398):291-303.

View in: PubMed
Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. Future Oncol. 2023 Feb; 19(5):385-395.

View in: PubMed
Galbiati M, Meroni M, Boido M, Cescon M, Rusmini P, Crippa V, Cristofani R, Piccolella M, Ferrari V, Tedesco B, Casarotto E, Chierichetti M, Cozzi M, Mina F, Cicardi ME, Pedretti S, Mitro N, Caretto A, Ris? P, Sala A, Lieberman AP, Bonaldo P, Pennuto M, Vercelli A, Poletti A. Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice. Neurotherapeutics. 2023 03; 20(2):524-545.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement